USD 36.0
(-7.98%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | - USD | -100.0% |
2022 | 56.15 Million USD | 733.93% |
2021 | 6.73 Million USD | -82.98% |
2020 | 39.56 Million USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | - USD | 0.0% |
2024 Q2 | - USD | 0.0% |
2023 Q1 | 87.94 Million USD | 56.61% |
2023 Q2 | 68.06 Million USD | -22.6% |
2023 Q3 | 33.96 Million USD | -50.1% |
2023 FY | - USD | -100.0% |
2023 Q4 | - USD | -100.0% |
2022 Q4 | 56.15 Million USD | 213.55% |
2022 Q3 | 17.91 Million USD | 23.78% |
2022 Q2 | 14.46 Million USD | -84.15% |
2022 Q1 | 91.28 Million USD | 13.24% |
2022 FY | 56.15 Million USD | 733.93% |
2021 FY | 6.73 Million USD | -82.98% |
2021 Q1 | 58.32 Million USD | 47.43% |
2021 Q4 | 80.6 Million USD | 7.67% |
2021 Q3 | 74.86 Million USD | 16.87% |
2021 Q2 | 64.05 Million USD | 9.82% |
2020 Q2 | 8.97 Million USD | 95.77% |
2020 FY | 39.56 Million USD | 0.0% |
2020 Q3 | 20.13 Million USD | 124.43% |
2020 Q1 | 4.58 Million USD | 0.0% |
2020 Q4 | 39.56 Million USD | 96.53% |
2019 Q2 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
ADC Therapeutics SA | 16.17 Million USD | 100.0% |
Alto Neuroscience, Inc. | - USD | NaN% |
Annovis Bio, Inc. | - USD | NaN% |
Ginkgo Bioworks Holdings, Inc. | 46 Thousand USD | 100.0% |
Nuvation Bio Inc. | - USD | NaN% |
Nuvation Bio Inc. | - USD | NaN% |
Arcus Biosciences, Inc. | - USD | NaN% |
Theriva Biologics, Inc. | - USD | NaN% |
Zymeworks Inc. | 1.00 USD | 100.0% |